To sum up, the combination of LAG-3 blockade with PD-1/PD-L1 blockade exhibits better anti-tumor effects than PD-1/PD-L1 blockade alone in clinic and preclinical studies, and this might be due to the co-expression of LAG3 and PD-1 at high levels in TILs within the TME. The gene discussed is PDCD1; the disease is neoplasm.